- Details
- Kevin Kelly discusses a groundbreaking approach to prostate cancer treatment with Alicia Morgans. He presents Xaluritamig (AMG 509) a novel bi-specific antibody targeting the STEAP1 protein, prevalent in prostate cancer cells. This innovative therapy, a form of biTE therapy, is designed to attract T-cells for targeted cytotoxicity. In a phase one trial involving advanced prostate cancer patients w...
|
- Details
- Zach Klaassen speaks with Dan George about a key study comparing Enzalutamide (Enza) and Abiraterone (Abi) in pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). This study addresses a significant gap in head-to-head clinical trials for these drugs. Dr. George discusses various data sources, including the French National Database, Flatiron, and VA data, all indicating a survi...
|
- Details
- Alicia Morgans and Rana McKay delve into the complexities of treatment sequencing for metastatic castration-resistant prostate cancer. They highlight the expansive range of available therapies, including hormonal, targeted, immunotherapies, chemotherapy, and radioligand therapies. The focus is on the importance of patient involvement in decision-making, considering individual preferences, lifestyl...
|
- Details
- In a discussion with Alicia Morgans, Oliver Sartor delves into the innovative PSMAfore trial, focusing on treating metastatic CRPC in taxane-naive patients using PSMA PET-positive lesions. This trial, evolving from the VISION trial, aims to expand treatment eligibility by initiating therapy before chemotherapy, addressing the fact that nearly half of metastatic prostate cancer patients never recei...
|
- Details
- Zach Klaassen and Ron Tutrone explore the promising data surrounding EPI-7386, an inhibitor of the androgen receptor. The conversation focuses on the phase two trial of EPI-7386 in combination with enzalutamide for treating metastatic castrate-resistant prostate cancer. Dr. Tutrone explains the unique mechanism of action of EPI-7386, which targets the N-terminal domain of the androgen receptors, u...
|
- Details
- The pivotal phase 3 VISION study used [68Ga]Ga-PSMA-11 (also known as 68Ga-PSMA-11) imaging to identify patients with metastatic castration-resistant prostate cancer eligible for [177Lu]Lu-PSMA-617 radioligand therapy, based on predefined read criteria. In this substudy of VISION, the inter-reader variability and intra-reader reproducibility of visual assessments of 68Ga-PSMA-11 positron emission...
|
- Details
- Phillip Koo and Daniel Saltzstein delve into the ECLIPSE clinical trial. The trial, aiming to enroll over 400 patients, brings Lutetium-177, a radioligand therapy, to patients with metastatic castrate-resistant prostate cancer at an earlier stage than it's currently approved for. Dr. Saltzstein outlines the trial's inclusion criteria, notably patients with castrated testosterone, PSA progression,...
|
- Details
- Alicia Morgans interviews Soumyajit Roy regarding his work on the COU-AA-302 data set, published in European Urology. The study investigates the effects of definitive prostate treatments, such as radiation therapy or radical prostatectomy, on outcomes when patients with metastatic castrate-resistant prostate cancer (mCRPC) are treated with abiraterone. Dr. Roy explains his motivation for the study...
|
- Details
- Elena Castro joins Alicia Morgans in a discussion on the clinical trial landscape for metastatic castration-resistant prostate cancer. When seeing a patient, Elena considers prior therapies and genetic testing, noting BRCA1 and BRCA2 alterations being investigated earlier provide an opportunity to treat patients with different PARP inhibitors. Drs. Morgans and Castro highlight the use of radiophar...
|
- Details
- Heather Cheng and Andrea Miyahira discuss the GENTleMEN study, which explored the feasibility of an internet-based, cost-free genetic testing program for men with metastatic prostate cancer. The study aimed to provide genetic testing to patients with advanced disease by removing barriers to access and cost and was launched in 2016 after research suggested that 25% of metastatic prostate cancer tum...
|